#ES­MO20: 'As good as any PD-1 out there': Re­gen­eron flash­es PD-(L)1 lung can­cer da­ta to ri­val Mer­ck

Re­gen­eron en­tered the PD-(L)1 game late, so they de­vised a two-pronged strat­e­gy to catch up with Big Phar­ma ri­vals: They would push it in­to can­cers where PD-1s had yet been test­ed, and they would prove that it’s as pow­er­ful in the big in­di­ca­tions as any oth­er on the mar­ket.

They cleared a hur­dle on the first goal Fri­day, show­ing a 31% re­sponse in pa­tients with the rare skin can­cer basal cell car­ci­no­ma. And with the da­ta they’re rolling out Mon­day, Re­gen­eron can­cer chief Is­rael Lowy is ready to de­clare suc­cess on the sec­ond.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER